On 15 November 2016, the European Commission (“the Commission”) opened its second report on Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12...08 December 2016
Outlook for 2015: Antitrust Litigation in the Pharma Industry - More Than Just Actavis Progeny
In 2014 there were a number of significant antitrust developments for the pharmaceutical industry. These involved not only challenges with respect to pharmaceutical patent litigation settlements (so-called “reverse payment” agreements), but also investigations and challenges to conduct related to product reformulations, Risk Evaluation and Mitigation Strategies (REMS), and FDA citizen petitioning activity.
The split of competences between the European Union (“EU”) and its Member States has been a point of friction in the setting out of the future European rules on unmanned...14 November 2016